Description
BSE announces addition of 3 securities to the Enhanced Surveillance Measure (ESM) framework effective March 11, 2026, along with the consolidated list of all securities under ESM.
Summary
BSE has updated the Enhanced Surveillance Measure (ESM) framework effective March 11, 2026. Three new securities have been shortlisted for inclusion in ESM Stage I. No securities are being moved to higher or lower ESM stages, and no securities are exiting the ESM framework in this update.
Key Points
- 3 new securities added to ESM framework (Stage I) effective March 11, 2026
- No securities moved to higher ESM stages
- No securities moved to lower ESM stages
- No securities removed from the ESM framework
- The consolidated ESM list contains securities across Stage I and Stage II
- Gem Aromatics Ltd (544491) added as per NSE designation
- Novateor Research Laboratories Ltd (542771) is an SME scrip
Regulatory Changes
The following securities are newly shortlisted under ESM Stage I w.e.f. March 11, 2026:
| Sr No | Scrip Code | ISIN | Scrip Name | Note |
|---|---|---|---|---|
| 1 | 544491 | INE06XZ01023 | Gem Aromatics Ltd | As per NSE |
| 2 | 539200 | INE203Q01026 | Noble Polymers Ltd | — |
| 3 | 542771 | INE08JY01013 | Novateor Research Laboratories Ltd | SME Scrip |
No securities are moving to higher or lower ESM stages, and no securities are exiting the ESM framework in this update cycle.
Compliance Requirements
- Market participants must note the revised ESM status of the three newly added securities effective March 11, 2026
- Trading members must comply with ESM trading conditions for all listed securities in the consolidated ESM list
- ESM conditions typically include: mandatory trade-for-trade settlement, reduced price bands, and additional margin requirements
- Investors holding or transacting in ESM-listed scrips must be aware of the applicable restrictions
Important Dates
- Circular Date: March 10, 2026
- Effective Date: March 11, 2026 (for newly added and all ESM status changes)
Impact Assessment
The addition of Gem Aromatics Ltd, Noble Polymers Ltd, and Novateor Research Laboratories Ltd to ESM Stage I will significantly impact liquidity and trading in these scrips. ESM Stage I imposes trade-for-trade settlement and tighter price bands, making speculative trading more difficult and increasing settlement risk for participants. Existing investors in these securities may face challenges in exiting positions due to reduced market depth. The fact that no securities are exiting ESM in this update indicates continued regulatory concern about market quality in the broader ESM universe. The consolidated list reflects ongoing surveillance across a large number of scrips spanning both Stage I and Stage II, with Stage II scrips facing even more stringent restrictions.
Impact Justification
Directly affects trading conditions for newly added securities under ESM; traders and investors in these scrips face significant restrictions including reduced price bands and mandatory trade-for-trade settlement.